Compare Stocks: MCRB, TNYA, SPRB, and CRBU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.23 -3.5%	$1.50	$1.22 ▼ $3.54	$132.40M	2.28	1.48 million shs	483,569 shs
MCRB Seres Therapeutics	$2.98 -11.2%	$4.69	$2.83 ▼ $29.98	$29.90M	0.21	70,295 shs	227,361 shs
SPRB Spruce Biosciences	$44.73 -7.9%	$51.57	$7.88 ▼ $240.00	$128.64M	3.31	64,416 shs	58,614 shs
TNYA Tenaya Therapeutics	$0.57 -5.4%	$0.70	$0.53 ▼ $2.35	$128.04M	2.77	3.44 million shs	4.02 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	+2.02%	-1.94%	-17.86%	-30.49%	-45.71%
MCRB Seres Therapeutics	-3.74%	-11.61%	-31.77%	-56.72%	-82.59%
SPRB Spruce Biosciences	+2.77%	-1.70%	-17.62%	-7.48%	+442.79%
TNYA Tenaya Therapeutics	+1.77%	-8.55%	-12.24%	-23.29%	-62.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.23 -3.5%	$1.50	$1.22 ▼ $3.54	$132.40M	2.28	1.48 million shs	483,569 shs
MCRB Seres Therapeutics	$2.98 -11.2%	$4.69	$2.83 ▼ $29.98	$29.90M	0.21	70,295 shs	227,361 shs
SPRB Spruce Biosciences	$44.73 -7.9%	$51.57	$7.88 ▼ $240.00	$128.64M	3.31	64,416 shs	58,614 shs
TNYA Tenaya Therapeutics	$0.57 -5.4%	$0.70	$0.53 ▼ $2.35	$128.04M	2.77	3.44 million shs	4.02 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	+2.02%	-1.94%	-17.86%	-30.49%	-45.71%
MCRB Seres Therapeutics	-3.74%	-11.61%	-31.77%	-56.72%	-82.59%
SPRB Spruce Biosciences	+2.77%	-1.70%	-17.62%	-7.48%	+442.79%
TNYA Tenaya Therapeutics	+1.77%	-8.55%	-12.24%	-23.29%	-62.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	2.80	Moderate Buy	$7.75	532.65% Upside
MCRB Seres Therapeutics	2.25	Hold	$17.00	471.43% Upside
SPRB Spruce Biosciences	2.77	Moderate Buy	$158.33	253.95% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	600.53% Upside

Current Analyst Ratings Breakdown

Latest MCRB, TNYA, SPRB, and CRBU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$144.00
9/18/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$149.00
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$123.00 ➝ $104.00
8/14/2026	CRBU Caribou Biosciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$6.00 ➝ $5.00
8/13/2026	SPRB Spruce Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$11.16M	11.77	N/A	N/A	$1.31 per share	0.94
MCRB Seres Therapeutics	$790K	37.85	$0.93 per share	3.20	$4.89 per share	0.61
SPRB Spruce Biosciences	$4.91M	26.15	N/A	N/A	$39.72 per share	1.13
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$148.12M	-$1.08	N/A	N/A	N/A	-1,030.42%	-89.11%	-62.47%	11/11/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest MCRB, TNYA, SPRB, and CRBU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRBU Caribou Biosciences	-$0.3240	-$0.24	+$0.0840	-$0.24	$2.28 million	$1.50 million
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	6.49	6.49
MCRB Seres Therapeutics	N/A	2.11	2.11
SPRB Spruce Biosciences	0.05	9.23	9.23
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
MCRB Seres Therapeutics	59.34%
SPRB Spruce Biosciences	91.71%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.54%
MCRB Seres Therapeutics	5.20%
SPRB Spruce Biosciences	4.30%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	97	107.21 million	98.05 million	Optionable
MCRB Seres Therapeutics	66	10.05 million	9.52 million	Optionable
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable
TNYA Tenaya Therapeutics	70	224.23 million	218.56 million	Optionable

MCRB, TNYA, SPRB, and CRBU Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Consensus Price Target of $4.00

September 30 at 4:46 AM | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Average Target Price of $4.00

September 30 at 4:13 AM | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 3.2% - Here's What Happened

September 28 at 12:39 AM | marketbeat.com

Tenaya Therapeutics Announces RMAT Designation To TN-401

September 14, 2026 | rttnews.com

Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up

September 14, 2026 | rttnews.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

September 14, 2026 | finance.yahoo.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

September 14, 2026 | globenewswire.com

Tenaya op H.C. Wainwright-conferentie: gentherapiedata

September 11, 2026 | nl.investing.com

Tenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYA

September 11, 2026 | benzinga.com

BlackRock Inc. Acquires New Stake in Tenaya Therapeutics, Inc. $TNYA

September 6, 2026 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Sell

September 6, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, TNYA, SPRB, and CRBU Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.23 -0.05 (-3.54%)

As of 03:56 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Seres Therapeutics NASDAQ:MCRB

$2.98 -0.38 (-11.19%)

As of 03:56 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$44.73 -3.85 (-7.92%)

As of 03:56 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.57 -0.03 (-5.40%)

As of 03:56 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, TNYA, SPRB, and CRBU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, TNYA, SPRB, and CRBU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, TNYA, SPRB, and CRBU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, TNYA, SPRB, and CRBU Company Descriptions

Caribou Biosciences NASDAQ:CRBU

Seres Therapeutics NASDAQ:MCRB

Spruce Biosciences NASDAQ:SPRB

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, TNYA, SPRB, and CRBU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, TNYA, SPRB, and CRBU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, TNYA, SPRB, and CRBU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, TNYA, SPRB, and CRBU Company Descriptions

Caribou Biosciences NASDAQ:CRBU

Seres Therapeutics NASDAQ:MCRB

Spruce Biosciences NASDAQ:SPRB

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools